- Home
- DNTH vs SITC Comparison
DNTH vs SITC Comparison
Compare DNTH & SITC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- SITC
- Stock Information
- Founded
- DNTH 2015
- SITC 1965
- Country
- DNTH United States
- SITC United States
- Employees
- DNTH N/A
- SITC N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- SITC Real Estate Investment Trusts
- Sector
- DNTH Health Care
- SITC Real Estate
- Exchange
- DNTH Nasdaq
- SITC Nasdaq
- Market Cap
- DNTH 724.8M
- SITC 786.5M
- IPO Year
- DNTH N/A
- SITC 1993
- Fundamental
- Price
- DNTH $18.14
- SITC $12.86
- Analyst Decision
- DNTH Strong Buy
- SITC Hold
- Analyst Count
- DNTH 8
- SITC 8
- Target Price
- DNTH $54.33
- SITC $35.25
- AVG Volume (30 Days)
- DNTH 362.0K
- SITC 1.1M
- Earning Date
- DNTH 03-11-2025
- SITC 04-29-2025
- Dividend Yield
- DNTH N/A
- SITC 4.10%
- EPS Growth
- DNTH N/A
- SITC 101.37
- EPS
- DNTH N/A
- SITC 9.77
- Revenue
- DNTH $6,235,000.00
- SITC $278,932,000.00
- Revenue This Year
- DNTH N/A
- SITC N/A
- Revenue Next Year
- DNTH N/A
- SITC N/A
- P/E Ratio
- DNTH N/A
- SITC $1.30
- Revenue Growth
- DNTH 120.63
- SITC N/A
- 52 Week Low
- DNTH $17.50
- SITC $12.47
- 52 Week High
- DNTH $32.27
- SITC $64.44
- Technical
- Relative Strength Index (RSI)
- DNTH 36.91
- SITC 39.49
- Support Level
- DNTH $17.50
- SITC $12.60
- Resistance Level
- DNTH $20.45
- SITC $13.27
- Average True Range (ATR)
- DNTH 1.67
- SITC 0.28
- MACD
- DNTH -0.22
- SITC 0.07
- Stochastic Oscillator
- DNTH 10.44
- SITC 48.12
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About SITC SITE Centers Corp.
SITE Centers Corp is a United States-based self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing and managing shopping centers.